Antitrust

$275M Sandoz and Fougera Antitrust Class Action Settlement

$275M Sandoz and Fougera Antitrust Class Action Settlement — Antitrust class action lawsuit

Case Overview

Sandoz Inc. and Fougera Pharmaceuticals Inc. have reached a settlement totaling $275 million to resolve claims that they participated in a conspiracy to raise and fix the prices of generic medications. This settlement is intended to benefit consumers and third-party payers who purchased, paid for, or reimbursed for generic drugs from these companies during the period spanning May 1, 2009, through December 31, 2019.

The plaintiffs in this multidistrict litigation alleged that generic drug manufacturers, including Sandoz and Fougera, colluded to manipulate and stabilize the pricing of generic drugs, which allegedly resulted in consumers and third-party payers overpaying for these necessary medications. Sandoz, an independent Swiss generic pharmaceuticals manufacturer, and its parent entity, Fougera, have not admitted any wrongdoing regarding these allegations.

Under the terms of the settlement, class members are eligible to receive a cash payment based on the amount they paid for covered drugs during the specified time frame; those who paid more will receive a larger portion of the fund. To claim benefits, individuals must submit a valid claim form by the deadline of November 9, 2026.

Who May Qualify

All persons and entities in the 50 United States (excluding Indiana and Ohio), the District of Columbia, Puerto Rico, and the U.S. Virgin Islands that indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price for any named generic drugs, other than for resale, from May 1, 2009, to December 31, 2019.

Frequently Asked Questions

Who is eligible for this settlement?

The settlement benefits all persons and entities located in the 50 United States (with exceptions for Indiana and Ohio), the District of Columbia, Puerto Rico, and the U.S. Virgin Islands. Eligibility requires having indirectly purchased, paid for, or provided reimbursement for named generic drugs, other than for resale, between May 1, 2009, and December 31, 2019.

What information do I need to prove my claim?

Consumers and third-party payers must provide specific details for each prescription, including the name of the pharmacy or mail-order pharmacy, the purchase date, the prescription number, the total out-of-pocket amount paid, and any amount paid by their health insurance plan.

What is the deadline to file a claim?

Class members must submit a valid claim form by November 9, 2026, to be considered for settlement benefits.

Related Cases

Major Airlines Price-Fixing Allegations — Antitrust class action lawsuit

Major Airlines Price-Fixing Allegations

Current
Antitrust
Two separate class action lawsuits have been filed against major airlines and ATPCO, alleging that the companies conspired to fix domestic airfares using shared data platforms. The plaintiffs claim this coordination resulted in artificially high ticket prices for consumers.
Blue Cross Antitrust Lawsuit Over Alleged Overcharging in Michigan — Antitrust class action lawsuit

Blue Cross Antitrust Lawsuit Over Alleged Overcharging in Michigan

Current
Antitrust
The state of Michigan filed an antitrust lawsuit against Blue Cross Blue Shield of Michigan Mutual Insurance Company, alleging the insurer violated antitrust laws by conspiring with other Blue Cross Blue Shield entities. The suit claims this conspiracy allowed the company to overcharge the state for administering employee medical benefit plans and harmed Michigan residents by limiting choice and quality in healthcare.
Amazon and Apple Class Action Lawsuit Over Inflated iPad Buy Box Prices — Antitrust class action lawsuit

Amazon and Apple Class Action Lawsuit Over Inflated iPad Buy Box Prices

Current
Antitrust
Two consumers initiated a class action lawsuit alleging that Amazon and Apple colluded to remove third-party resellers from Amazon's marketplace, which allegedly resulted in inflated prices for iPads.